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Summary
Objective: To characterize the in vivo role epiphycan (Epn) has in cartilage development and/or maintenance.
Methods: Epn-deﬁcient mice were generated by disrupting the Epn gene in mouse embryonic stem cells. Epn/biglycan (Bgn) double-deﬁcient
mice were produced by crossing Epn-deﬁcient mice with Bgn-deﬁcient mice. Whole knee joint histological sections were stained using van
Gieson or Fast green/Safranin-O to analyze collagen or proteoglycan content, respectively. Microarray analysis was performed to detect
gene expression changes within knee joints.
Results: Epn-deﬁcient and Epn/Bgn double-deﬁcient mice appeared normal at birth. No signiﬁcant difference in body weight or femur length
was detected in any animal at 1 month of age. However, 9-month Epn/Bgn double-deﬁcient mice were signiﬁcantly lighter and had shorter
femurs than wild type mice, regardless of gender. Male Epn-deﬁcient mice also had signiﬁcantly shorter femurs than wild type mice at
9 months. Most of the deﬁcient animals developed osteoarthritis (OA) with age; the onset of OA was observed earliest in Epn/Bgn double-
deﬁcient mice. Message RNA isolated from Epn/Bgn double-deﬁcient knee joints displayed increased matrix protein expression compared
with wild type mice, including other small leucine-rich proteoglycan (SLRP) members such as asporin, ﬁbromodulin and lumican.
Conclusion: Similar to other previously studied SLRPs, EPN plays an important role in maintaining joint integrity. However, the severity of the
OA phenotype in the Epn/Bgn double-deﬁcient mouse suggests a synergy between these two proteins. These data are the ﬁrst to show a ge-
netic interaction involving class I and class III SLRPs in vivo.
ª 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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Epiphycan (Epn), a chondroitin/dermatan sulfate proteogly-
can preferentially expressed in epiphyseal cartilage during
embryonic development1, is a member of the small leu-
cine-rich proteoglycan (SLRP) family. SLRPs are extracel-
lular matrix (ECM) molecules that contain a tandem array
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88C-terminal cysteines. Many SLRP core proteins are also
substituted with glycosaminoglycan (GAG) chain(s), al-
though the presence, nature, and size of the GAGs appear
to be tissue-speciﬁc and age-dependent2.
SLRPs are divided into three classes based upon the
spacing of their N-terminal cysteines, the number of LRRs
they contain, and their corresponding gene structures.
Class I (decorin, biglycan, and asporin) and class II SLRPsted equally to this work.
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89Osteoarthritis and Cartilage Vol. 18, No. 1(ﬁbromodulin, proline/arginine-rich end leucine-rich repeat
protein (PRELP), keratocan, lumican, and osteoadherin/
osteomodulin) contain 10e12 LRRs, whereas class III
SLRPs (EPN/PG-Lb/DSPG3, opticin, and osteoglycin/
mimecan) contain 6e8 LRRs. Chondroadherin, NYX/nycta-
lopin, ECM2, podocan, and nephrocan contain both the
N-terminal cysteine cluster and the LRR domain character-
istics of SLRPs but are not assigned to a class.
SLRPs interact with a variety of ECM proteins. Reported
binding partners include ﬁbronectin3, thrombospondin4, ﬁ-
brinogen5, heparin cofactor II6, complement component 1 q
(C1q)7e9, mannose-binding lectin10, collectin 4310, congluti-
nin10, pulmonary surfactant D11, and transforming growth
factor-beta (TGF-beta)12,13. The most commonly reported
binding partner for SLRP proteins is collagen14. Moreover,
the targeted disruption of individual SLRPs can lead to obvi-
ous collagen ﬁbril formation defects in vivo. However, single
SLRP-deﬁcient mice display relatively mild phenotypes
when considering their tissue distributions; an observation
that suggests some SLRPs may compensate for the loss
of others. For example, lumican-null mice exhibit corneal
clouding and skin laxity, but do not show signiﬁcant alter-
ations in tendon stiffness15. However, lumican loss-of-func-
tion enhances the reduced tendon stiffness seen in
ﬁbromodulin-null mice, suggesting that lumican compen-
sates for the loss of ﬁbromodulin16. This putative genetic in-
teraction is particularly interesting in light of the fact that
ﬁbromodulin and lumican bind to a similar site on collagen17.
Many different SLRPs are expressed in cartilage, including
asporin, biglycan, chondroadherin, decorin, EPN, ﬁbromodu-
lin, keratocan, lumican, opticin, and PRELP18e23. However,
the ability of SLRPs to inﬂuence osteoarthritis (OA) progres-
sion is not understood. Furthermore, increased SLRP degra-
dation has been detected in human osteoarthritic cartilage
samples24. Such degradation presumably leads to cartilage
matrix destabilization. Recent reports have implicated one
particular SLRP, asporin, with hip and knee OA in Asian pop-
ulations25,26. A speciﬁc human polymorphism in the asporin
gene, resulting in an N-terminal region that contains 14 as-
partic acid residues rather than 13 aspartic acid residues, is
signiﬁcantly associated with individuals that have OA.
Very little is reported about class III SLRPs, particularly
Epn. Epn expression appears to be restricted to cartilage
and testis27. The unique tissue expression of Epn in chick28
and mouse27 cartilage suggests that this SLRP may play
a key role in chondrocyte differentiation and, hence, carti-
lage stability. To further investigate this possibility, we gen-
erated and characterized Epn-deﬁcient mice. These mice
exhibit a very mild skeletal phenotype. Since biglycan
(Bgn) is also expressed in mouse cartilage, and may com-
pensate for the loss of Epn, Epn/Bgn double-deﬁcient ani-
mals were also generated and characterized.Materials and methodsGENERATION OF Epn-DEFICIENT AND Epn/Bgn
DOUBLE-DEFICIENT MICEAn 8 kb fragment of the 129S6 mouse Epn gene was identiﬁed with a rat
Epn probe and used to construct the targeting vector, which contained
a LacZ expression cassette followed by a neomycin (neo)-resistance gene
ﬂanked by loxP sites. A MC-1 thymidine kinase cassette was included imme-
diately outside the homologous mouse sequence of the targeting vector.
MouseAB2.2 embryonic stemcells (ESC; a gift fromAllanBradley) were elec-
troporated with the linearized targeting vector described above using a BioRad
GenePulser and grown inM15media containingG418 to select for cells contain-
ing theneo-resistance gene. The targeting vectorwasdesigned to insert the LacZ
cassette six base pairs downstream of and in frame with the starting ATG codon.
ESC clones containing the correct insertion were identiﬁed by Southern blothybridizationand injected intoC57BL/6J albinoblastocysts according to standard
procedures. High percentage coat-color-contribution chimaeras were crossed
with C57BL/6J albino mice to obtain germline transmission of the targeted allele.
Southern blot and PCR analyses were used to genotype the mice.
Double heterozygous Epn/Bgn mice (F1 generation) were produced by inter-
crossing homozygous Bgn-deﬁcient females (Epnþ/þBgn/) with homozygous
Epn-deﬁcient males (Epn/Bgnþ/0). The production and characterization of
Bgn-deﬁcient mice was previously described29. Epn/Bgn knockout mice (F2)
were obtained by intercrossing F1 double heterozygous Epn/Bgn mice. All of
the mice were maintained in a hybrid 129S6:C57BL/6J albino genetic back-
ground. Each animal experiment was approved by the Institute of Biosciences
and Technology Institutional Animal Care and Use Committee.SOUTHERN BLOT ANALYSISMouse ESC genomic DNA was digested with ScaI or BglII. Southern blot
hybridization was performed according to the procedure of Ramı´rez-Solis
et al.30 with radiolabeled 50 or 30 probes that hybridized to regions of the
Epn gene lying outside of the targeting vector homology.POLYMERASE CHAIN REACTION (PCR)The PCR scheme for the Bgn allele was performed as described previ-
ously29. To identify the Epn genotype of each mouse, the following primers
were used in separate PCR reactions: a forward primer (Epn1fw) correspond-
ing to sequences inEpn exon II (50GGTCAGGGGCAAATACCAAGGACTCT),
a reverse primer (Epn2rv) corresponding to sequences in Epn exon III (50-
CTCTACATGG TTGTCAGGAATGTG), and a second forward primer (Bpa)
corresponding to a sequence containedwithin the bovine growth hormone pol-
yadenylation signal sequence of the neo cassette (50-GCTTCTGAGGCG-
GAAAGAACCAGCTA). The ampliﬁed PCR product for the wild type Epn
allele with primer pair Epn1fw/Epn2rv was 2.6 kb, whereas the product for
the disrupted Epn allele with primer pair Bpa/Epn2rv was 0.4 kb.BODY WEIGHT AND FEMUR LENGTH DETERMINATIONThe body weights and femur lengths of each mouse was measured at 1
and 9 months of age. Femur length was measured under a dissecting micro-
scope using calibers. The data from 13e40 different mice per genotype of
each gender were analyzed using the KruskaleWallis test followed by
a Dunn’s multiple comparison post-test.HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STAININGAll tissues were ﬁxed in either 4% paraformaldehyde or 10% formalin, de-
calciﬁed at room temperature in 0.5 M ethylenediaminetetraacetic acid
(EDTA) for 1 week, dehydrated in ascending concentrations of alcohol,
and parafﬁn-embedded. Serial sections were cut from the parafﬁn block us-
ing a microtome and thereafter dewaxed and rehydrated. For histological
analysis of collagen content, tissue sections were stained with hematoxylin
for 2 min followed by immersion in van Gieson stain for 5 min. The remaining
sections were stained with hematoxylin for 2 min, brieﬂy differentiated in
acidiﬁed alcohol, and stained with 0.2% Fast green for 2 min. After washing
with 1% acetic acid, the sections were stained with Safranin-O for 3 min to
examine tissue morphology and proteoglycan content.
Immunohistochemical stainingwasperformedusingpolyclonal antibodies that
detect either mouse BGN (LF-159) or mouse EPN (R561). The rabbit polyclonal
anti-BGN antibody, LF-15931, was a gift from Dr. Larry Fisher (NIH/NIDCR, Be-
thesda, MD). The polyclonal anti-EPN antibody, R561, was raised in rabbits
against puriﬁed recombinant EPN protein (Ala18-Thr111 fused at the C-terminus
to glutathione S-transferase; Alpha Diagnostics International, San Antonio, TX).
R561 antibody characterization demonstrated that it is speciﬁc for EPN. Tissue
sections were digested with 4 mg/ml hyaluronidase in phosphate buffered saline
(PBS) at 37C for 30 min prior to immunostaining. The sections were then incu-
bated with R561 (1:1000) or LF-159 (1:2000) overnight at 4C. Antibody staining
was visualized with the Vectastain Elite ABC immunoperoxidase kit (Vector Lab-
oratories, Hercules, CA). Hematoxylin was used as a counterstain.OA GRADING AND SCORINGSerial sagittal histological sections of individual mouse knee joints were exam-
ined for signs of OA in a double-blind fashion. The slides were scored for OA se-
verity usedagrading systembasedupon the criteriaofMaierandWilhelmi32. This
system uses the following scale to quantify OA severity: grade 0 indicates no ap-
parent changes, grade 1 indicates slight ﬁbrillation of the articular cartilage, grade
2 speciﬁes defects limited to the uncalciﬁed cartilage, grade 3 speciﬁes defects
penetrating into thecalciﬁedcartilage,andgrade4 indicatessubchondralboneex-
posure at the joint surface. Scores for each genotype were averaged and ana-
lyzed using an unpaired Student’s t-test withWelch’s and Bonferroni corrections.
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ANALYSISMales were chosen for these experiments because they displayed increased
joint disease severity as compared to females.Epn/Bgndouble-deﬁcient andwild
type mice were sacriﬁced at 3 months of age (n¼ 3 for each genotype). The
tibialefemoral joints of each male mouse were harvested by dissecting the joint
immediately above the femoral condylesand immediately below the tibial plateau,
measuringapproximately 1 cm in length.Skin, tendons, and ligamentsaround the
joint were removed for reproducibility of the procedure. The joint tissue was then
immediately frozen in liquid nitrogen and pooled forRNA isolation (for a total of six
joints per genotype). Total RNA was isolated using TRIzol-mediated organic
extraction (Invitrogen, Carlsbad, CA) followed by puriﬁcation with RNeasy mini11.4kb
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RNA integrity was assessed using formaldehyde gel electrophoresis.
Second-strand cDNA was generated from 5 mg of joint tissue RNA using
an oligo(dT)-T7 promoter primer and SuperScript II reverse transcriptase
(Invitrogen, Carlsbad, CA). Complementary RNA (cRNA) was ampliﬁed
from the cDNA and biotinylated using the BioArray High Yield RNA Tran-
script Labeling Kit (ENZO, Farmingdale, NY) according to the manufacturer’s
instructions. After puriﬁcation, labeled cRNA was quantiﬁed using a spectro-
photometer and fragmented in 200 mM Tris/acetate (pH 8.1), 500 mM potas-
sium acetate, and 150 mM magnesium acetate for 35 min at 94C. The
fragmented cRNA was then hybridized overnight to the Mouse Genome
430A 2.0 GeneChip (Affymetrix, Santa Clara, CA). The resultant signal
was detected according to the manufacturer’s instructions. This procedureScaI BglIIBglII
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91Osteoarthritis and Cartilage Vol. 18, No. 1was repeated three times for each genotype; a different cRNA preparation
was used for each hybridization event. All six arrays were analyzed using
the dChip software package (www.dchip.org). Each array had a different
level of overall brightness; the dChip program was therefore used to
normalize arrays to the median intensity level using an invariant-set
normalization method33. After normalization, expression values were
calculated using a perfect match model34. The program parameters were
set such that expression values at least 1.25-fold and an absolute
difference of more than 100 between wild type and double-deﬁcient
samples were detected.ResultsGENERATION AND INITIAL CHARACTERIZATION OF
Epn-DEFICIENT MICEThe Epn locus was disrupted in mouse embryonic stem
cells by inserting a targeting vector into exon III downstream
of the endogenous Epn translation start codon [Fig. 1(A)].
Southern blot analysis veriﬁed that the Epn locus was cor-
rectly targeted, generating bands of the predicted fragment
size [Fig. 1(B and C)]. The genotypes of the mice were con-
ﬁrmed using PCR [Fig. 1(D)]. Homozygous Epn-deﬁcientFig. 2. Immunohistological analysis of murine knee joints using the anti-E
B, and D are oriented in the same manner, with the femur on the left an
Epn-deﬁcient tibialefemoral joint. AC¼ articular cartilage and GP¼ gr
tibialefemoral joint. EPN is detected in the growth plate and articular car
showing very weak expression of EPN protein in the growth plate. D, L
joint. BGN is detected in the growth plate,mice were born with the expected Mendelian ratio, ap-
peared healthy at birth, and were fertile. LacZ activity was
not detected in the mutant embryos for unknown reasons.
EPN protein was undetectable in Epn-deﬁcient mice at
any age [Fig. 2(A)]. In contrast, EPN protein was ob-
served in wild type newborn mice within the ECM of all
cartilaginous zones except the cartilage immediately ad-
jacent to the joint cavitation space and the perichondrium
(data not shown1). At 2 weeks of age, EPN was detected
in the deep layer of articular cartilage of wild type mice,
but not within the superﬁcial layer [Fig. 2(B)]. EPN was
also detected in growth plate cartilage. Very weak EPN
staining was observed in the growth plate cartilage of
2-month-old wild type mice [Fig. 2(C)]. EPN protein was
not detected in wild type mice older than 2 months
(data not shown). The distribution of EPN protein in
Bgn-deﬁcient mice was similar to that described above
for wild type mice (data not shown). Control sections
from wild type mice where the anti-EPN antibody
(R561) was omitted from the staining procedure showed
no background (data not shown).PN antibody, R561, or the anti-BGN antibody, LF-159. Panels A,
d the tibia on the right. A, R561 antibody staining of a 2-week-old
owth plate. B, R561 antibody staining of a 2-week-old wild type
tilage. C, R561 antibody staining of a 2-month-old wild type femur
F-159 antibody staining of a 2-week-old wild type tibialefemoral
articular cartilage, and the meniscus.
92 S. Nuka et al.: Characterization of EPN-deﬁcient miceThe localization of EPN protein within the tibialefemoral
joint strongly resembles the localization of another SLRP,
biglycan [Fig. 2(D)]. Since biglycan genetically interacts
with another SLRP molecule, ﬁbromodulin35, Epn-deﬁcient
mice were bred with biglycan (Bgn)-deﬁcient mice to test
whether biglycan genetically interacts with epiphycan. Sim-
ilar to Epn-deﬁcient mice, Epn/Bgn-deﬁcient mice were born
in the expected Mendelian ratio, appeared healthy at birth,
and were fertile.BODY WEIGHT AND FEMUR LENGTHDue to the fact that EPN and BGN are found within the
cartilage growth plate of long bones, we examined the
body weights and femur lengths of our SLRP-deﬁcient
mice. No signiﬁcant difference in body weight was detected
between the different genotypes at 1 month of age, regard-
less of gender (Fig. 3). At 9 months, the body weights of
male Epn- and Bgn-deﬁcient mice were also similar to their
wild type littermates. However, 9 month-old-male Epn/Bgn
double-deﬁcient mice were signiﬁcantly lighter by 17.1%
(P< 0.001). No signiﬁcant difference in body weight was
detected between 9-month-old wild type and Epn-deﬁcientMales
9 months
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Fig. 3. Mean body weights of wild type and SLRP-deﬁcient mice at 1 and 9
weight as compared to wild type mice (P< 0.001). Thefemales. However, the body weights of both Bgn- and
Epn/Bgn-deﬁcient females were 16.3% lighter than their
wild type littermates at 9 months (P< 0.001).
Next, the ability of EPN and/or BGN to inﬂuence the growth
of long bones was examined. The average femur length of
1-month-old Epn-, Bgn-, or Epn/Bgn double-deﬁcient mice
was not signiﬁcantly different than the average femur length
of wild type mice, regardless of the gender. However, the
femur lengths of 9-month-old male Epn- and Epn/Bgn dou-
ble-deﬁcient mice were signiﬁcantly shorter than their wild
type littermates by 3.9% (P< 0.05) and 7.1% (P< 0.001), re-
spectively. Male Bgn-deﬁcient femurs were not signiﬁcantly
shorter than wild type at this age. For females, only Epn/
Bgn double-deﬁcient femurs were signiﬁcantly shorter than
wild type at 9 months (by 7%, P< 0.001).HISTOLOGYTo further assess joint tissue morphology and proteogly-
can content, histological sections of tibialefemoral joints
from four 9-month-old animals per genotype were charac-
terized by hematoxylin/eosin and Safranin-O staining. His-
tological evidence of premature OA was not observed in9 months
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months of age. The asterisks denote a signiﬁcant difference in body
error bars denote the S.E.M. for each genotype.
93Osteoarthritis and Cartilage Vol. 18, No. 1joint sections from wild type mice [Fig. 4(A)]. However, os-
teoarthritic signs were observed in two of the four Epn-deﬁ-
cient mice, including articular surface ﬁbrillations and
signiﬁcant proteoglycan loss [Fig. 4(B)]. Similar observa-
tions were made in three of the four Bgn-deﬁcient mice ex-
amined [Fig. 4(C)]. The Bgn-deﬁcient mice also showed
evidence of ligament and tendon ossiﬁcation (data not
shown), in agreement with Ameye et al36. The most severe
OA-like phenotype was observed in Epn/Bgn double-deﬁ-
cient animals [Fig. 4(D)]; joint sections from all four animals
showed damaged articular cartilage that was often com-
pletely eroded to the underlying bone, which was typically
sclerotic. Epn/Bgn double-deﬁcient mice showed increased
osteophyte formation within and around the joint space. In-
creased ligament and tendon ossiﬁcation was also detected
in these mice (data not shown).
To quantify the observed OA-like changes detected in
our SLRP-deﬁcient mice, histological sections of tibialefe-
moral joints from male mice of each genotype at various
ages were examined in a double-blind fashion and scored
using the OA grading system devised by Maier and Wil-
helmi32. Compared to wild type mice, a number of the
Epn- and Bgn-deﬁcient mice began to display OA-like
changes at 6 and 4 months of age, respectively (Fig. 5).
Epn/Bgn double-deﬁcient mice appeared to develop OA-
like characteristics even sooner, as early as 3 months.
Additionally, the OA grade in double-deﬁcient mice was
highly signiﬁcant at 6 months, 3 months earlier than Bgn-
deﬁcient mice. Epn-deﬁcient mice displayed OA-like
changes that were only of borderline signiﬁcance at 9
months of age. Signiﬁcant OA-like changes were also de-
tected in female Epn/Bgn double-deﬁcient mice, although
these were less severe (data not shown).Fig. 4. Safranin-O staining of the tibialefemoral joint in 9-month-old mice.
the picture. A, Representative joint section from a wild type animal. B, R
sentative joint section from a Bgn-deﬁcient mouse. D, Representative join
panels B, C, and D denote ﬁbrillation as well asCOLLAGEN CONTENT ANALYSISSince OA is associated not only with aggrecan but also
collagen loss, we examined histological sections of male
tibial-femoral joints for total collagen content using van Gie-
son stain at 2, 3, and 6 months. A difference in collagen
staining when compared to wild type mice was detected
within the superﬁcial zone of articular cartilage in Bgn-deﬁ-
cient and Epn/Bgn-deﬁcient mice as early as 3 months
(Fig. 6). Collagen loss consistently appeared to be more
pronounced at the articular surface of Epn/Bgn double-deﬁ-
cient mice when compared to Bgn-deﬁcient mice (Fig. 6 in-
set). This was accompanied by a deﬁciency of superﬁcial
chondrocytes. Epn-deﬁcient mice showed similar collagen
staining when compared to wild type mice (data not shown).MICROARRAY ANALYSISTo examine what happens at the molecular level before
signiﬁcant OA-like morphological changes occur, we
compared the mRNA proﬁle of whole knee joints from
3-month-old wild type and Epn/Bgn double-deﬁcient male
mice. We chose to analyze changes in the whole joint for
two reasons: (1) OA is a disease of the whole joint and
(2) In our experience, it is extremely difﬁcult to obtain mouse
cartilage samples that are not contaminated with other tis-
sues, such as subchondral bone.
We detected a signiﬁcant increase in the mRNA of 49
separate genes within Epn/Bgn double-deﬁcient mice as
compared to wild type mice. A total of seven speciﬁc
mRNAs were signiﬁcantly decreased at this time point in
the disease progression; the largest decrease detected
was for (mRNA) Bgn (further conﬁrmation that the miceIn each panel, the femur is at the top and the tibia is at the bottom of
epresentative joint section from an Epn-deﬁcient mouse. C, Repre-
t section from an Epn/Bgn double-deﬁcient mouse. The asterisks in
articular cartilage and proteoglycan loss.
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Fig. 5. Mean scores of OA severity in male wild type and SLRP-de-
ﬁcient mice. Sections of the tibialefemoral joint in wild type, Epn-
deﬁcient, Bgn-deﬁcient, and Epn/Bgn double-deﬁcient mice were
scored for OA using the criteria of Maier and Wilhelmi (30). A min-
imum of four mice were examined at every age for each genotype.
The age of the mice in months is given on the x-axis, while the OA
grade is shown on the y-axis. The error bars denote the S.E.M. for
each genotype. *P 0.053, **P¼ 0.036, and ***P< 0.005 com-
pared to wild type mice at that age. With Bonferroni correction,
a P value of 0.02 is necessary to reach statistical signiﬁcance.
94 S. Nuka et al.: Characterization of EPN-deﬁcient micewere Bgn-deﬁcient; (mRNA) Epn is not expressed at this
age in wild type mice).
The majority of mRNAs that were increased in double-deﬁ-
cient mice corresponded to secreted proteins. Of the genes
encoding ECM proteins, the a1 chain of type III procollagen
showed the largest increase (Table I). ThemRNAs of metallo-
proteinases MMP-2 and MMP-14, as well as the serine prote-
ase HtrA1, were also increased in Epn/Bgn double-deﬁcient
mice. Interestingly, three other SLRPs (asporin, ﬁbromodulin,
and lumican) were signiﬁcantly up-regulated in double-deﬁ-
cient mice. A complete description of all the gene changes
canbe found in theNationalCenter for Biotechnology Informa-
tion Gene Expression Omnibus (GSE9099).
Discussion
We previously showed that (mRNA) Epn has a highly re-
stricted expression pattern within cartilage1, suggesting thatFig. 6. Collagen analysis in tibialefemoral joints. Sections of 3-month-old
Epn/Bgn double-deﬁcient mice were stained with van Giesen to analyze
magniﬁed image of the area denoit plays a role in skeletal formation and/or maintenance. The
generation of Epn-deﬁcient mice demonstrated that al-
though EPN is not essential for embryonic skeletal develop-
ment, it is critical for proper long bone growth and joint
maintenance. For example, EPN signiﬁcantly inﬂuences fe-
mur length in male mice. This effect is presumably due to
subtle defects in the growth plate since EPN is not ex-
pressed in bone. Furthermore, EPN is necessary for retain-
ing cartilage integrity with age because EPN loss, in the
absence of BGN, signiﬁcantly accelerates the rate of OA-
like lesion development when compared to their single
SLRP-deﬁcient littermates. The rapid progression of OA in
the double-deﬁcient mouse suggests one of two possibili-
ties: (1) EPN and BGN have some overlapping functions
within cartilage or (2) EPN and BGN have independent
functions that, when deleted, exacerbate the progression
of OA. Future work will be necessary to demonstrate which
possibility is correct. Nevertheless, our data are the ﬁrst to
show an in vivo genetic interaction involving class I and
class III SLRPs.
Our collagen content analysis in the tibialefemoral joints
of SLRP-deﬁcient animals demonstrated that collagen loss
occurred at the articular cartilage surface in both Bgn-deﬁ-
cient and Epn/Bgn double-deﬁcient mice. However,
collagen loss appeared to be greater in Epn/Bgn double-de-
ﬁcient animals. These data imply that EPN inﬂuences the
stability of the collagen matrix in a Bgn-deﬁcient back-
ground, again suggesting that BGN and EPN share a func-
tion in maintaining joint integrity. Collagen loss in mutant
animals preceded signiﬁcant OA-like changes as measured
by the Maier and Whilhelmi OA grading scale and may
therefore be responsible for increasing their susceptibility
to develop OA. In human osteoarthritic cartilage samples,
collage degradation37 and loss of collagen tensile
strength38 is detected early in the disease. Interestingly, in-
creased collagen degradation has been observed either be-
fore37 or at a similar time as proteoglycan loss39. Future
studies to investigate whether this apparent loss of collagen
staining is due to increased collagen degradation are
underway.
Epn/Bgn double-deﬁcient mice are not the only SLRP-de-
ﬁcient mice that develop OA-like changes. Previous work
has shown that Bgn-deﬁcient35, ﬁbromodulin-deﬁcient40,
Bgn/ﬁbromodulin double-deﬁcient35, and lumican/ﬁbromo-
dulin double-deﬁcient mice16 also develop an OA-like
disease. In all of the cases examined thus far, the double-
deﬁcient mice develop OA earlier than their single SLRP-
deﬁcient counterparts, demonstrating the necessity formale mouse tibialefemoral joints from wild type, Bgn-deﬁcient, and
collagen content. The image at the top left of each panel is a 6-fold
ted by the black box (n¼ 3).
Table I
Genes of proteins found in the ECM that are regulated in Epn/Bgn
double-deficient mice
3-month-old Epn/Bgn
deﬁcient vs WT
Gene Fold change
Procollagen, type III, a1 5.78
Asporin 3.07
Syndecan 2 2.69
Follistatin-like 2.67
Fibrillin 1 2.44
Dermatopontin 2.38
Superoxide dismutase 3, extracellular 2.35
Annexin VIII 2.32
Insulin-like growth factor 1 2.29
Procollage, type VI, a1 2.26
Procollagen, type VI, a2 2.22
Lumican 2.12
HtrA1 peptidase 2.06
Fibromodulin 2.04
Procollagen, type VI, a3 1.92
Fibronectin 1 1.92
Procollagen C-proteinase enhancer protein 1.88
Matrix metalloproteinase 2 1.87
Thrombospondin 4 1.86
Procollagen, type V, a1 1.76
Procollagen, type IV, a2 1.63
Marix metalloproteinase 14 1.59
Biglycan 36.07
95Osteoarthritis and Cartilage Vol. 18, No. 1multiple SLRPs to maintain joint integrity. The SLRP-mu-
tants described above also show tendon abnormalities
that likely contribute toward OA development and/or
progression.
We currently do not know why the absence of a protein
that is apparently only expressed early in life, such as
EPN, would show effects later in life. However, there are
several possible explanations. Firstly, EPN could be re-
quired for stabilizing the cartilage matrix through its ability
to inﬂuence collagen ﬁbrillogenesis, matrix assembly, or
chondrocyte-ECM interactions. The fact that other SLRPs
are known to inﬂuence collagen ﬁbril formation and our col-
lagen content analysis support this possibility. Secondly,
EPN may inﬂuence one or more currently undeﬁned cell
signaling events that are necessary for proper chondro-
cyte/cartilage maintenance. This idea is supported by the
recent work of Schaefer et al.41, where BGN was shown
to signal through TLR-2 and TLR-4. Thirdly, EPN may be re-
quired for repairing localized joint damage. In this scenario,
a currently undetectable, localized expression of EPN by
chondrocytes possibly helps to repair matrix defects that ac-
cumulate throughout life. Fourthly, EPN may directly or indi-
rectly inﬂuence the structure of the subchondral bone
matrix. EPN loss would therefore lead to cartilage degener-
ation because of the altered subchondral bone structure.
The answer may also be a combination of the possibilities
listed above.
We also do not know the reason behind the gender differ-
ences reported herein. For example, femurs are signiﬁ-
cantly shorter in male but not female Epn-deﬁcient mice
when compared to wild type mice. Sex hormone and/or
body weight differences may play a role. However, future
work is needed to fully understand these effects. Generally
speaking, gender differences in genetically manipulated
mice are not well studied, although there a few examples re-
ported in the literature (e.g., Bgn/Fibromodulin-deﬁcient
mice35 and estrogen receptor-knockout mice42).Interestingly, our microarray analysis of Epn/Bgn double-
deﬁcient mice detected increased ECM gene expression
that can also be seen in human OA samples43e46. These in-
clude the mRNAs of the type III collagen a chain43,45, matrix
metalloproteinase 243,45, ﬁbronectin43,45,46, lumican47, and
ﬁbromodulin47. Furthermore, we detected increases in
mRNAs that are known to be increased at the protein level
in human osteoarthritic cartilage, including type VI collagen
protein48, annexin VIII protein49, and insulin-like growth fac-
tor 1 protein50. However, our microarray data also suggests
that superoxide dismutase 3 is increased in Epn/Bgn dou-
ble-deﬁcient tissue; this protein has actually been shown
to be decreased in human osteoarthritic cartilage and in
a naturally occurring OA mouse model, STR/ort51. This dis-
crepancy may be due to the fact that the tissues are not
identical (whole joints vs cartilage alone).
Of interest, the mRNA levels of three different SLRPs (as-
porin, ﬁbromodulin, and lumican) are increased in Epn/Bgn
double-deﬁcient mice as compared with wild type mice.
These data suggest that the expression of various SLRPs
are somehow interrelated and may be further proof of the
ability of SLRP molecules to compensate for each other.
Taken together, the data presented herein suggests that
Epn/Bgn double-deﬁcient mice may be a useful tool for the
study of OA. The tibialefemoral joints from Epn/Bgn double-
deﬁcient mice show similar morphological changes to
human OA joints, including articular cartilage erosions, pro-
teoglycan loss, subchondral bone sclerosis, and osteophyte
growth. While our deﬁcient mice are not the only OA murine
model to be proposed, their usefulness lies in the fact that
signiﬁcant characteristics of the disease are detected fairly
quickly (by 6 months) with complete penetrance. Further-
more, our model has the potential to shed light on how
SLRPs inﬂuence the molecular events that lead to OA.
The fact that many different genetic and physical manipula-
tions in mice cause an OA-like phenotype suggests that
joint health is maintained by a variety of factors. Since hu-
man OA is thought to be a multifactorial disease, we believe
that the use of multiple murine models, including SLRP-de-
ﬁcient mice, is necessary to best understand OA disease
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